| Autor: |
Mallah N; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain.; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBER-ESP), Madrid, Spain.; Department of Preventive Medicine, University of Santiago de Compostela (USC), Santiago de Compostela, Spain., Pardo-Seco J; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain.; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBER-ES), Instituto de Salud Carlos III, Madrid, Spain., Rivero-Calle I; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain.; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBER-ES), Instituto de Salud Carlos III, Madrid, Spain.; Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago de Compostela and USC, Santiago de Compostela, Spain., Zhu-Huang O; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain.; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBER-ES), Instituto de Salud Carlos III, Madrid, Spain., Fernández Prada M; Servicio de Medicina Preventiva y Salud Pública, Hospital Vital Álvarez Buylla, Asturias, Spain., Reynen-de Kat C; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Benes O; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Mosina L; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Sankar-Datta S; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Aleksinskaya O; English-Russian medical interpreter/translator, Russian Federation., Díaz D; Head of Design and Development Marketing agency, Sisuco Solutions, Madrid, Spain., Allahverdiyeva V; World Health Organization Country Office in Ukraine, Kyiv, Ukraine., Grechukha Y; World Health Organization Country Office in Ukraine, Kyiv, Ukraine., Jobava T; Digital Marketing Consultant & Project Manager, World Health Organization, Georgia., Savchyna M; World Health Organization Country Office in Ukraine, Kyiv, Ukraine., Kortusova P; World Health Organization Country Office, Czechia., Novac I; World Health Organization Country Office, Bucharest, Romania., Martinón-Torres F; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain.; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBER-ES), Instituto de Salud Carlos III, Madrid, Spain.; Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago de Compostela and USC, Santiago de Compostela, Spain. |
| Abstrakt: |
COVID-19 vaccine uptake varied across countries, in part due to vaccine hesitancy fueled by a lack of trustworthy information. To help health workers provide evidence-based answers to common questions about COVID-19 vaccines and vaccination, and thereby, assist individuals´ decisions on vaccine acceptance, COVID-19 InfoVaccines, a joint WHO-EU project, was launched in February 2021 to support COVID-19 vaccine rollout in 6 Eastern European countries. COVID-19 InfoVaccines was made available in seven languages and shared on social media networks. A total of 262,592 users accessed COVID-19 InfoVaccines.com between February 11, 2021, and January 31 st , 2023. The users were most interested in: general questions; vaccine efficacy and duration of protection; vaccine safety; vaccine co-administration, and dose-interval and interchangeability; though the interest in a specific theme varied in function of the epidemiological situation. A total of 118,510 (45.1%) and 46,644 (17.7%) users scrolled up to 35% and 75% of the COVID-19 InfoVaccines webpage, respectively. The average engagement rate was 71.61%. The users accessed COVID-19 InfoVaccines from 231 countries and territories, but the majority were in Ukraine ( N = 38,404; 14.6%), Spain ( N = 23,327; 8.9%), and Argentina ( N = 21,167; 8.1%). Older Facebook users were more interested in COVID-19 information than younger individuals ( X 2 p-value < .0001). Two hundred twenty-eight videos were shared on YouTube. The average Click-Through-Rate on Facebook was 7.82%, and that on YouTube was 4.4%, with 60 videos having a Click-Through-Rate >5%, falling in the range of average YouTube video Click-Through-Rate (2% - 10%). As misinformation about vaccines and vaccination spreads easily and can negatively impact health-related decisions, initiatives like COVID-19 InfoVaccines are crucial to facilitate access to reliable information. |
